Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
NNNN
Strong SellAnbio Biotechnology · Healthcare · Germany · $347M · Avg Vol: $972K/d
18
StockRankGet insider-trade alerts
Q
73
V
20
M
6
P/E (TTM)
51.5x
ROE
27.0%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
Information for Anbio Biotechnology under ticker NNNN is not publicly available, as NNNN is not a valid public stock ticker and Anbio Biotechnology is primarily a private company.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|---|
| Revenue | — | 23.5M | 6.7M | 8.2M | 8.6M | -28.4% | 8.6M |
| EPS | 0.03 | 0.07 | 0.02 | 0.05 | 0.15 | 54.9% | 0.15 |
| Shares | — | 43.9M | 43.9M | 43.9M | 43.9M | 0.0% | 43.9M |
| Debt | — | — | — | — | — | — | — |
| Equity | — | 12.5M | 14.8M | 17.2M | 30.2M | 33.9% | — |
| Op CF | — | 4.4M | 0.9M | 2.1M | -6.7M | -31.6% | -6.7M |
| Inv CF | — | -1.5M | 1.7M | 0.3M | -4.2M | — | — |
| Fin CF | — | 0 | -42.8K | -0.3M | 6.9M | — | — |
Loading 1Y...
PRICE (1Y)-19.4%
SMA 50SMA 200
Close
$7.67
RSI (14)
28.6
52W High
$51.33
From 52W High
0.1%
SCORE BREAKDOWN
Quality
73
ROIC
19.1%90.3
ROE
27.0%93.5
GP/Assets
24.9%56.3
Op. Margin
59.1%98.7
FCF/Assets
-31.8%12.9
Piotroski
560.1
Int. Cover
50.0x89.3
D/E Ratio
0.00x97.9
Current Ratio
344.31x99.9
Value
20
P/E (TTM)
51.5x20.0
EV/EBITDA
—N/A
P/FCF
—N/A
P/B
11.2x10.2
P/S
39.2x11.4
Div Yield
—N/A
Momentum
6
52W High %
15%1.8
RS 6M
-83%2.3
SMA 50/200
0.46x1.8
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$347M
P/E (Forward)
—
Gross Margin
87.2%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NNNN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| NNNN | Anbio Biotechnology(you) | $347M | 18 | Strong Sell |
| GXI.DE | Gerresheimer AG | $1.1B | 56 | Hold |
| AFX.DE | Carl Zeiss Meditec AG | $3.3B | 77 | Buy |
| FIE.DE | Fielmann Group AG | $3.9B | 77 | Buy |
| EVT.DE | Evotec SE | $679M | 20 | Sell |
| SRT.DE | Sartorius Aktiengesellschaft | $15.5B | 58 | Hold |
| FYB.DE | Formycon AG | $380M | 36 | Hold |
| IFRX | InflaRx N.V. | $302M | 39 | Hold |
| VRXA | Veraxa Biotech AG | $252M | 1 | Strong Sell |
| QUCY | Quantum Cyber N.V. | $110M | 21 | Sell |
Peer medians: ROE 6.9% · P/E 16.5x · Gross margin 45.4%